Form 4: Vera Therapeutics Director Acquires 14,000 Stock Options

Michael Morrissey, a director of Vera Therapeutics, acquired 14,000 stock options at an exercise price of $42.69 on May 15, 2024.

Summary

• On May 15, 2024, Michael Morrissey, a director of Vera Therapeutics, acquired 14,000 stock options.
• The exercise price for these options is $42.69.
• The options vest fully on the earlier of the first anniversary of the grant date or the date of the Company's 2025 annual stockholder meeting, contingent upon continuous service.
• The options also vest fully upon a change in control, subject to continuous service through the date of such change in control.
• The expiration date for the options is May 14, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative performance, but rather transparency.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future prospects.

Future Outlook

The vesting of the options is tied to continued service and a potential change in control, suggesting a focus on long-term commitment and strategic events.

Industry Context

Form 4 filings are routine disclosures of insider transactions, providing transparency into the actions of company directors and officers. This filing indicates a director's increased stake in the company's equity.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates